{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:26:27Z","timestamp":1789683987439,"version":"4.0.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The musculoskeletal toxicity of immune checkpoint inhibitors (ICIs) is receiving increasing attention with clinical experience. Nevertheless, the absence of a systematic investigation into the musculoskeletal toxicity profile of ICIs currently results in the under-recognition of associated adverse events. Further and more comprehensive investigations are warranted to delineate the musculoskeletal toxicity profile of ICIs and characterize these adverse events.<\/jats:p><jats:p><jats:bold>Material and methods:<\/jats:bold> The present study employed the FDA Adverse Event Reporting System database to collect adverse events between January 2010 and March 2021. We utilized both the reporting odds ratio and the Bayesian confidence propagation neural network algorithms to identify suspected musculoskeletal adverse events induced by ICIs. Subsequently, the clinical characteristics and comorbidities of the major musculoskeletal adverse events were analyzed. The risk of causing these events with combination therapy <jats:italic>versus<\/jats:italic> monotherapy was compared using logistic regression model and \u03a9 shrinkage measure model.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The musculoskeletal toxicity induced by ICIs primarily involves muscle tissue, including neuromuscular junctions, fascia, tendons, and tendon sheaths, as well as joints, spine, and bones, including cartilage. The toxicity profile of PD-1\/PD-L1 and CTLA-4 inhibitors varies, wherein the PD-1 inhibitor pembrolizumab exhibits a heightened overall risk of inducing musculoskeletal adverse events. The major ICIs-induce musculoskeletal adverse events, encompassing conditions such as myositis, neuromyopathy (including myasthenia gravis, Lambert-Eaton myasthenic syndrome, Guillain-Barr\u00e9 syndrome, and Chronic inflammatory demyelinating polyradiculoneuropathy), arthritis, fractures, myelitis, spinal stenosis, Sjogren\u2019s syndrome, fasciitis, tenosynovitis, rhabdomyolysis, rheumatoid myalgia, and chondrocalcinosis. Our study provides clinical characteristics and comorbidities of the major ICIs-induced musculoskeletal adverse events. Furthermore, the combination therapy of nivolumab and ipilimumab does not result in a statistically significant escalation of the risk associated with the major musculoskeletal adverse events.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Immune checkpoint inhibitors administration triggers a range of musculoskeletal adverse events, warranting the optimization of their management during clinical practice.<\/jats:p>","DOI":"10.3389\/fphar.2023.1199031","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T04:29:13Z","timestamp":1696912153000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study"],"prefix":"10.3389","volume":"14","author":[{"given":"Hao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongchi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"105168","DOI":"10.1016\/j.jbspin.2021.105168","article-title":"Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: Consequences on overall survival","volume":"88","author":"Adda","year":"2021","journal-title":"Jt. Bone Spine"},{"key":"B2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1248\/bpb.b19-00156","article-title":"Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS","volume":"42","author":"Ando","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann. Rheumatic Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s11864-022-00995-9","article-title":"Immune checkpoint inhibitor rechallenge after prior immune toxicity","volume":"23","author":"Bylsma","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"13479","DOI":"10.3390\/ijms232113479","article-title":"Molecular and genetic mechanisms of spinal stenosis formation: Systematic review","volume":"23","author":"Byvaltsev","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.41587","article-title":"Expert perspective: Immune checkpoint inhibitors and rheumatologic complications","volume":"73","author":"Cappelli","year":"2021","journal-title":"Arthritis & Rheumatology (Hoboken, N.J.)."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet (London, Engl."},{"key":"B9","doi-asserted-by":"publisher","first-page":"612259","DOI":"10.3389\/fphar.2020.612259","article-title":"Inflammasome targeted therapy in pregnancy: New insights from an analysis of real-world data from the FAERS database and a systematic review","volume":"11","author":"Carnovale","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Sci. (New York, N.Y.)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/art.41949","article-title":"Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer","volume":"74","author":"Cunningham-Bussel","year":"2022","journal-title":"Arthritis & Rheumatology (Hoboken, N.J.)."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1111\/bcp.15361","article-title":"Thromboembolic events in janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the food and drug administration's adverse event reporting system","volume":"88","author":"Dong","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ijc.33592","article-title":"Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis","volume":"149","author":"Filippini","year":"2021","journal-title":"Int. J. Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/art.42406","article-title":"Early increase of circulating transitional B cells and autoantibodies to joint-related proteins in patients with metastatic melanoma developing checkpoint inhibitor-induced inflammatory arthritis","volume":"75","author":"Gatto","year":"2022","journal-title":"Arthritis & Rheumatology (Hoboken, N.J.)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1097\/RHU.0000000000001777","article-title":"Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: A systematic literature review","volume":"28","author":"Ghosh","year":"2022","journal-title":"J. Clin. Rheumatology Pract. Rep. Rheumatic Musculoskelet. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v077.b02","article-title":"ggplot2-elegant graphics for data analysis","volume":"77","author":"G\u00f3mez-Rubio","year":"2017","journal-title":"J. Stat. Softw."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e003066","DOI":"10.1136\/jitc-2021-003066","article-title":"Immune checkpoint inhibitors in patients with pre-existing psoriasis: Safety and efficacy","volume":"9","author":"Halle","year":"2021","journal-title":"J. For Immunother. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and management of myositis-associated lung disease","volume":"163","author":"Hallowell","year":"2023","journal-title":"Chest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"585311","DOI":"10.3389\/fonc.2020.585311","article-title":"Biomarkers of checkpoint inhibitor induced immune-related adverse events-A comprehensive review","volume":"10","author":"Hommes","year":"2020","journal-title":"Front. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front. Neurology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1007\/s00432-022-04516-x","article-title":"Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea","volume":"149","author":"Hyun","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA a Cancer J. For Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/sj.clpt.6100233","article-title":"An evaluation of computer-aided disproportionality analysis for post-marketing signal detection","volume":"82","author":"Lehman","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2288-14-17","article-title":"Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases","volume":"14","author":"Leroy","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"105457","DOI":"10.1016\/j.jbspin.2022.105457","article-title":"Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer","volume":"90","author":"Melia","year":"2023","journal-title":"Jt. Bone Spine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.spinee.2006.09.009","article-title":"Nonoperatively treated burst fractures of the thoracic and lumbar spine in adults: A 23- to 41-year follow-up","volume":"7","author":"Moller","year":"2007","journal-title":"Spine J. Official J. North Am. Spine Soc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","article-title":"Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: A seminal case series","volume":"6","author":"Moseley","year":"2018","journal-title":"J. For Immunother. Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"884776","DOI":"10.3389\/fphar.2022.884776","article-title":"Immune checkpoint inhibitor-related myositis overlapping with myocarditis: An institutional case series and a systematic review of literature","volume":"13","author":"Nakagomi","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","article-title":"Review of statistical methodologies for detecting drug-drug interactions using spontaneous reporting systems","volume":"10","author":"Noguchi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000529816","article-title":"Clinical features focusing on extraintestinal manifestations in Japanese patients with inflammatory bowel diseases: Far east 1000","volume":"104","author":"Ohta","year":"2023","journal-title":"Digestion"},{"key":"B34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semarthrit.2020.09.020","article-title":"Antisynthetase syndrome - much more than just a myopathy","volume":"51","author":"Opinc","year":"2021","journal-title":"Seminars Arthritis Rheumatism"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1136\/annrheumdis-2019-216599","article-title":"Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis","volume":"79","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann. Rheumatic Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00019052-200206000-00009","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy","volume":"15","author":"Pollard","year":"2002","journal-title":"Curr. Opin. neurology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/JIPO.JIPO_12_19","article-title":"Rheumatic and musculoskeletal adverse events with immune checkpoint inhibitors: Data from the United States food and drug administration adverse event reporting system","volume":"2","author":"Pundole","year":"2019","journal-title":"J. Immunother. Precis. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B39","doi-asserted-by":"publisher","first-page":"101805","DOI":"10.1016\/j.berh.2022.101805","article-title":"Treatment of rheumatic adverse events of cancer immunotherapy","volume":"36","author":"Reid","year":"2022","journal-title":"Best Pract. Res. Clin. Rheumatology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e003260","DOI":"10.1136\/jitc-2021-003260","article-title":"Activated osteoarthritis following immune checkpoint inhibitor treatment: An observational study","volume":"9","author":"Reid","year":"2021","journal-title":"J. For Immunother. Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: Cancer immunotherapy in patients with preexisting rheumatic disease: The mayo clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis & Rheumatology (Hoboken, N.J.)."},{"key":"B42","doi-asserted-by":"publisher","first-page":"103146","DOI":"10.1016\/j.msard.2021.103146","article-title":"Drug-related demyelinating syndromes: Understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings","volume":"55","author":"Rimkus","year":"2021","journal-title":"Multiple Scler. Relat. Disord."},{"key":"B43","doi-asserted-by":"publisher","first-page":"uxad032","DOI":"10.1093\/cei\/uxad032","article-title":"What do we know about co-stimulatory and co-inhibitory immune checkpoint signals in ankylosing spondylitis?","author":"Sch\u00fctz","year":"2023","journal-title":"Clin. Exp. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e0246195","DOI":"10.1371\/journal.pone.0246195","article-title":"Dehydroepiandrostenedione sulphate (DHEAS) levels predict high risk of rheumatoid arthritis (RA) in subclinical hypothyroidism","volume":"16","author":"Shukla","year":"2021","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA a Cancer J. For Clin."},{"key":"B46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2165\/11586990-000000000-00000","article-title":"Reporting patterns indicative of adverse drug interactions: A systematic evaluation in VigiBase","volume":"34","author":"Strandell","year":"2011","journal-title":"Drug Saf."},{"key":"B47","doi-asserted-by":"publisher","first-page":"20420188231157194","DOI":"10.1177\/20420188231157194","article-title":"Immune checkpoint inhibitors: Friend or foe for osteoporosis","volume":"14","author":"Tang","year":"2023","journal-title":"Ther. Adv. Endocrinol. Metabolism"},{"key":"B48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends--an update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B52","doi-asserted-by":"publisher","first-page":"702482","DOI":"10.3389\/fendo.2021.702482","article-title":"Graves' disease and rheumatoid arthritis: A bidirectional mendelian randomization study","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Endocrinol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"B54","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00198-023-06690-1","article-title":"Fracture rate increases after immune checkpoint inhibitor treatment: A potential new immune related adverse event","volume":"34","author":"Ye","year":"2023","journal-title":"Osteoporos. Int."},{"key":"B55","doi-asserted-by":"publisher","first-page":"778635","DOI":"10.3389\/fimmu.2022.778635","article-title":"Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1199031\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T04:29:16Z","timestamp":1696912156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1199031\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":55,"alternative-id":["10.3389\/fphar.2023.1199031"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1199031","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"article-number":"1199031"}}